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of 12 months and cycle lengths of 1 month was designed
to evaluate the cumulative costs over time of plastic and
metal stent. A meta-analysis of all published randomised
trials was performed to derive the transitional probabili-
ties for ﬁrst and second occlusion and for death. A
national health care perspective was adopted. Unit cost
data was obtained from available public sources in
France, Sweden and England. Resource use was derived
from expert opinions in each country. RESULTS: Initial
procedural costs were higher with metal than with plastic
stents: the cost difference was €953 for Sweden, €739 for
France and €653 for England. However, due to fewer
reinterventions for exchange, follow-up costs were sub-
stantially reduced with metal stents. In Sweden and
England, the cost break-even point was after 4 months
and for patients with longer survival, metal stents became
cost-saving. In France, the break-even point was after 5
months. At 12 months, the difference per patient cost in
favour of metal was €493 for France, €620 for England
and €1002 for Sweden. CONCLUSION: This analysis
demonstrates that initial metal stent placement can be a
cost-saving strategy, especially if the patient survives 
more than 4 to 5 months. The higher procedural cost 
with a metal stent is offset by a reduction in re-treatment
costs. Avoiding reinterventions will beneﬁt patients in
terms of quality of life and the health care system as a
whole.
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OBJECTIVES: With a prevalence of 10% asthma is the
most common chronic disease among children and ado-
lescents in Germany. Approaches to reduce the burden of
asthma comprise patient education as a well-recognised
and effective component that helps to improve self-
management skills. We determined whether a continuous
internet-based education programme (IEP) as an add-on
to traditional education improves health outcomes of
asthma patients (8–16 years) at a favourable beneﬁt-cost
ratio. METHODS: We performed a prospective cost-
beneﬁt analysis alongside a non-randomised trial. A total
of 438 patients in 34 study centres in Germany were
enrolled in the investigation. Study participants were
assigned to a control group and two intervention groups.
Patients in both intervention groups received traditional
patient education. In one group patients received addi-
tional self-management education through the IEP for the
duration of 6 months. At the initial visit and at 6 and 12
months health service utilisation data were collected.
RESULTS: Utilisation of various Health care services (e.g.
number of consultations, urgent medical examinations)
decreased signiﬁcantly in both intervention groups. In the
ﬁrst year after intervention traditional education realised
morbidity cost savings of 333 EUR per patient. Adding
the IEP provided incremental savings of €143. From a
payer perspective, the beneﬁt-cost ratio of the traditional
education programme was 0.45. Adding the IEP im-
proved the ratio (0.69). For patients with moderate or
severe asthma the beneﬁt-cost ratio were 1.07 and 1.42
(with IEP). In individuals who had experienced an emer-
gency visit due to asthma 6 months prior to the study
entry, the ratios were 1.11 and 1.21, respectively. CON-
CLUSIONS: As a supplementary to traditional asthma
education programmes, the IEP offers the potential to
realise incremental morbidity savings. Subgroup analyses
demonstrated that within 1-year morbidity cost savings
surpass the intervention costs in patients who belong to
risk groups.
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OBJECTIVES: Patients who survived an acute myocar-
dial infarction (MI) have an increased risk for subsequent
major cardiovascular events and cardiac (often sudden)
death. The use of highly puriﬁed omega-3 polyunsatu-
rated fatty acids (n-3 PUFAs) in addition to standard 
secondary prevention after MI was associated with a sig-
niﬁcant reduction in risk of sudden death. Our study
assessed the cost-effectiveness (CE) of adding n-3 PUFAs
treatment to the current secondary prevention treatment
after acute MI in Belgium. METHODS: Based on the clin-
ical outcomes of the GISSI-prevenzione study (MI, stroke,
revascularisation rate and mortality) a decision model
was built in DataTM Pro. Adding n-3 PUFAs to standard
treatment was compared to standard treatment alone in
patients with a recent history of MI (age = 59 years) from
the health care payer’s perspective. The time horizon 
of the model was 3.5 years (identical to the GISSI-
prevenzione study). The cost of non-fatal events was
based on Belgian literature data and the cost of cardiac
death on a patient chart review (n = 60). The unit cost of
n-3 PUFAs was €1.25. Life expectancy data for cardiac
disease were obtained from published sources and
adjusted to the Belgian population. Results are expressed
as cost (€) per life year gained (LYG). RESULTS: Treat-
ment with n-3 PUFAs results in 0.287 life years gained at
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an additional cost of €1479. The incremental CE was
€5154/LYG (95% conﬁdence interval (CI) €3833/LYG-
€9944/LYG). Sensitivity analyses on effectiveness, cost of
complications and discounting shows the robustness 
of the results. A 2nd order Monte Carlo analysis based
on the 95% CI obtained in the GISSI study showed that
in 99.1% of patients n-3 PUFAs is a cost-effective treat-
ment option if €20,000/LYG is taken as a threshold.
CONCLUSIONS: Adding n-3 PUFAs to standard treat-
ment in the secondary prevention after MI appears cost-
effective in Belgium.
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OBJECTIVES: The cost-effectiveness of hypolipemiant
treatment with lovastatin (HMG-CoA reductase
inhibitor, 20, 40 and 80mg/day), cholestyramine (bile
acid sequestrant, 12 and 24g/day) gemﬁbrozil (ﬁbrate,
1,2g/day) in individuals with hypercholesterolemia 
>200mg/day was assessed in this study. METHODS:
Cost-effectiveness was measured in terms of met cost per
life year gained (LYG) comparing costs and beneﬁts in
Spain. The net treatment cost was deﬁned as the total cost
including medication, control measures and treatment of
adverse side effects less savings from coronary heart
disease costs. Effectiveness was measured using the Fram-
ingham equation, the information about the prevalence
of cardiovascular risk factors, and life expectancy accord-
ing to age and sex in Catalonia. Cost and beneﬁts were
discounted using a 5% discount rate. RESULTS: The
ranking list of efﬁciency in both men and women and for
different pre-treatment cholesterol levels was: lovastatin
20mg/day, cholestyramine 12g/day, lovastatin 40mg/day,
gemﬁbrozil 1.2g/day, cholestyramine 24g/day, and lovas-
tatin 80mg/day. Cost-effectiveness in terms of cost per
LGY ranged from $15,487 to 289,116 in men and from
$52,403 to 604,809 in women, according to age, sex, and
cholesterol concentration. In individuals with a choles-
terol concentration of 300mg/dl cost-effectiveness ranged
from $33,850 to 142,910 per LYG in men and from
$104,100 to 350,660 per LYG in women. The highest
cost-effectiveness was obtained in men aged 40–44 years
with 380mg/dl of cholesterol and in women aged 50–54
years with 380mg/dl of cholesterol, while the lowest cost-
effectiveness was observed in both men and women aged
70–75 years with 200mg/dl of cholesterol. Incremental
cost-effectiveness analysis showed that treating individu-
als with hypercholesterolemia using lovastatin was more
cost-effective than using cholestyramine and gemﬁbrozil.
CONCLUSION: This study has shown that lovastatin, an
HMG Co-A reductase inhibitor, was the most cost-
effective hypolipemiant drug assessed in this study.
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OBJECTIVES: To evaluate the effectiveness in the modi-
ﬁcation of cardiovascular risk (CVR) according to WHO-
ISH guidelines of an educative personalized interven-
tion in hypertensive (HT) patients in primary care.
METHODS: Observational, prospective and controlled
study. Two hundred seventy-nine general practitioners
(GP) were recruited throughout Spain. HT patients were
followed for six months. Investigators were cluster-ran-
domized to Control group (CG) and Intervention group
(IG). The CG investigators did usual clinical practice,
whereas IG investigators did usual clinical practice plus a
personalized educative intervention, which consisted in
the ad hoc printing by using a speciﬁc software of educa-
tive leaﬂets oriented to the modiﬁcation of life habits and
to control of cardiovascular risk factors for each patient.
RESULTS: HT patients totaling 4,019 were evaluated.
Both groups were comparative at baseline with respect to
sociodemographic variables and CVR distribution. The
IG showed a statistically signiﬁcant and clinically relevant
improvement in hypertension control (54.1% of con-
trolled hypertension in IG vs. 48.0% in CG; p < 0.01).
The ﬁnal CVR distribution was signiﬁcantly better in the
IG than in the CG. The IG patients improved signiﬁcantly
their knowledge of hypertension disease (from 36.8% to
80.6% of good knowledge in IG vs from 32.5% to 70.0%
in CG; p < 0.001). There were no differences in the evo-
lution of smoking, cholesterol and obesity. The overall
satisfaction with medical care was higher in the IG. Of
the patients, 90.9% answered “Always” to the question
“When you talk to your physician, does he/she answer
clearly to your questions?” vs 51.5% of patients in CG
(p < 0.05). CONCLUSION: The proposed procedure for
the personalized educative activity with the hypertensive
patient has proven to be feasible and useful for hyper-
tension and CVR control in general practitioners. The
intervention seems to improve knowledge about hyper-
tension and satisfaction level with medical care.
